Iterion Therapeutics
Stephen Horrigan has extensive work experience in the field of research and scientific leadership. Stephen began their career in 2000 as the Vice President of Research at Avalon Pharmaceuticals, where they worked until 2009. From there, they joined PGxHealth as the Vice President of Research until 2010. In 2010, they became the Chief Scientific Officer at Noble Life Sciences Inc and held that position until 2011. Stephen then moved to Iterion Therapeutics, where they currently serve as the Chief Scientific Officer.
Stephen Horrigan completed their education at Syracuse University, where they earned a Bachelor of Science degree in Biology from 1979 to 1985. Stephen then pursued further studies at the same institution and obtained a Ph.D. in Biology from 1985 to 1990.
This person is not in any teams
This person is not in any offices
Iterion Therapeutics
Iterion Therapeutics is a venture-backed, clinical-stage biotechnology company that develops novel targeted cancer therapeutics. The company’s lead product, Tegavivint, is a potent and selective inhibitor of the Wnt/b-catenin signaling pathway, implicated in cell proliferation, differentiation, immune evasion, and stem cell renewal. Tegavivintdemonstrates pre-clinical in vivo efficacy in several cancer models including desmoid tumors, acute myeloid leukemia (AML), osteosarcoma, and a range of solid tumor types. The Company is currently enrolling a Phase I clinical study of Tegavivint in patients with desmoid tumors at multiple clinical centers in the United States and Canada.It was founded in 2010 and is headquartered in Houston, Texas.